Avalo Therapeutics Inc (AVTX) Implied Volatility Current

Tracking AVTX implied volatility helps you identify when options premiums on Avalo Therapeutics Inc are historically cheap or expensive, and where the best trades are hiding. Avalo Therapeutics Inc implied volatility reflects the market's expectation of future price movement: when AVTX IV rises, option premiums increase, creating opportunities for sellers, and when it drops, buyers can find cheaper contracts. Use our scanner to monitor Avalo Therapeutics Inc's implied volatility current levels in real time and filter for high-probability trades.

Implied volatility is derived from option prices using models like Black-Scholes and represents the annualized expected move of an underlying stock. For AVTX, tracking metrics like AVTX IV rank helps traders understand whether current implied volatility is historically high or low. IV rank compares today's reading against the past year's range — a high rank on AVTX signals rich premiums and potential mean-reversion, while a low rank may favor long options strategies.

Avalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases. It develops AVTX-002, a fully human anti-LIGHT monoclonal antibody, which is under Phase II clinical trial for the treatment of non-eosinophilic asthma, as well as inflammatory bowel disease, including moderate to severe Crohn's disease, and ulcerative colitis; and Phase III clinical trial for the treatment of COVID-19 acute respiratory distress syndrome. The company also engages in developing AVTX-007, a fully human Anti-IL-18 monoclonal antibody that is under Phase I clinical trial for the treatment of still's disease, including adult-onset still's disease and systemic juvenile idiopathic arthritis.

Its products for rare genetic diseases in Phase III clinical trials include AVTX-801, a D-galactose substrate replacement therapy for the treatment of phosphoglucomutase 1 deficiency (PGM1), also known as PGM1-CDG; and AVTX-803, a L-fucose substrate replacement therapy for the treatment of LADII, also known as SLC35C1-CDG. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.

Premium sellers, directional traders, and spread builders all need the same starting point: a clear read on where AVTX implied volatility sits today versus where it has been. Our scanner ranks Avalo Therapeutics Inc implied volatility against its historical range, surfaces extremes in AVTX IV rank, and pairs every reading with the trades that exploit it. Stop guessing whether Avalo Therapeutics Inc IV is rich or cheap — measure it, then act on it.